Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling

Cell Communication and Signaling

Volumn 13, Issue 1, 2015, Pages

  Rizk, Shahir S ^a,b   Kouadio, Jean Louis K ^a,c   Szymborska, Anna ^a,d   Duguid, Erica M ^a   Mukherjee, Somnath ^a   Zheng, Jiamao ^e   Clevenger, Charles V ^e,f   Kossiakoff, Anthony A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c MONSANTO COMPANY   (United States)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e NORTHWESTERN UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Allostery; Phage display; Prolactin signaling; Synthetic antibody

Indexed keywords

ANTIBODY; GROWTH HORMONE; PROLACTIN; PROLACTIN RECEPTOR; REAGENT; SYNTHETIC ANTIBODY; UNCLASSIFIED DRUG; EPITOPE; HUMAN GROWTH HORMONE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ALLOSTERISM; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; BIOENGINEERING; CRYSTAL STRUCTURE; HORMONE BINDING; HORMONE TRANSPORT; INTERNALIZATION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; CHEMISTRY; GENETICS; HUMAN; PROTEIN TERTIARY STRUCTURE;

EPITOPES; HUMAN GROWTH HORMONE; HUMANS; PROLACTIN; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES;

EID: 84928690628     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-014-0080-8     Document Type: Article

References (12)

1. Krieger M, Stern DM. Series introduction: multiligand receptors and human disease. J Clin Invest. 2001;108:645-7.
2. Broutin I, Jomain JB, Tallet E, van Agthoven J, Raynal B, Hoos S, et al. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. J Biol Chem. 2010;285:8422-33.
3. Clevenger CV, Gadd SL, Zheng J. New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab. 2009;20:223-9.
4. Somers W, Ultsch M, De Vos AM, Kossiakoff AA. The X-ray structure of a growth hormone-prolactin receptor complex. Nature. 1994;372:478-81.
5. Cunningham BC, Bass S, Fuh G, Wells JA. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 1990;250:1709-12.
6. Walsh ST, Kossiakoff AA. Crystal structure and site 1 binding energetics of human placental lactogen. J Mol Biol. 2006;358:773-84.
7. Rizk SS, Paduch M, Heithaus JH, Duguid EM, Sandstrom A, Kossiakoff AA. Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins. Nat Struct Mol Biol. 2011;18:437-42.
8. van Agthoven J, Zhang C, Tallet E, Raynal B, Hoos S, Baron B, England P, Goffin V, Broutin I. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. J Mol Biol. 2010;404:112-126.
9. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24:1-27.
10. Otte JM, Otte C, Beckedorf S, Schmitz F, Vonderhaar BK, Folsch UR, et al. Expression of functional prolactin and its receptor in human colorectal cancer. Int J Colorectal Dis. 2003;18:86-94.
11. Fellouse FA, Esaki K, Birtalan S, Raptis D, Cancasci VJ, Koide A, et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol. 2007;373:924-40.
12. Fang F, Antico G, Zheng J, Clevenger CV. Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol. 2008;8:11.